舒泰神股价跌5.02%，华宝基金旗下1只基金重仓，持有2.04万股浮亏损失4.14万元

Group 1 - The core point of the article highlights the recent decline in the stock price of Shutaishen, which fell by 5.02% to 38.43 CNY per share, with a trading volume of 1.195 billion CNY and a turnover rate of 6.71%, resulting in a total market capitalization of 18.361 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, Huabao Fund has one fund heavily invested in Shutaishen, specifically Huabao Anying Mixed A (010868), which held 20,400 shares in the second quarter, accounting for 0.54% of the fund's net value, ranking as the eighth largest holding [2] - The estimated floating loss for Huabao Anying Mixed A today is approximately 41,400 CNY [2] - Huabao Anying Mixed A was established on June 8, 2021, with a current scale of 140 million CNY. Year-to-date returns are 9.09%, ranking 5991 out of 8246 in its category, while the one-year return is 15.93%, ranking 6375 out of 8054 [2]